Company Encyclopedia
View More
name
AN2 Therapeutics
ANTX.US
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company’s initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc.
4.729 T
ANTX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    AN2 Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    ANTX
    -3.51%
    LB filings·
    US
    ANTX
    -3.51%

    AN2 Therapeutics | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    ANTX
    -3.51%
    LB filings·
    US
    ANTX
    -3.51%

    AN2 Therapeutics Advances Chagas Disease and Oncology Programs and Reports Third Quarter 2025 Results

    AN2 Therapeutics Inc. reported its third quarter 2025 financial results, highlighting progress in its clinical pipeline. The company is advancing a Phase 1 trial for oral AN2-502998 targeting Chagas disease and plans a Phase 2 study with DNDi. Additionally, its M. abscessus program is in an investigator-initiated trial. In oncology, AN2 aims to develop boron-based targets for solid tumors, with a collaboration with GSK for TB inhibitors and continued funding from the Gates Foundation.

    Reuters·
    US
    ANTX
    -3.51%
    Reuters·
    US
    ANTX
    -3.51%

    AN2 Therapeutics Q3 net loss narrows to $9.4 mln

    AN2 Therapeutics reported a Q3 net loss of $9.4 million, an improvement from $12.7 million last year. R&D expenses decreased to $7 million from $8.3 million. The company is advancing its Phase 1 trial for Chagas disease and plans to initiate a Phase 2 study in 2026. AN2 projects cash reserves to sustain operations into 2028. The average analyst rating is "buy" with a 12-month price target of $1.50, reflecting a 20% increase from its recent closing price of $1.20.

    Reuters·
    US
    ANTX
    -3.51%
    Reuters·
    US
    ANTX
    -3.51%

    AN2 Therapeutics Partners with GSK to Develop Boron-Based Tuberculosis Treatments

    AN2 Therapeutics Inc. has partnered with GSK to develop boron-based LeuRS-inhibitors for tuberculosis treatment, supported by funding from the Gates Foundation. This collaboration aims to create innovative therapies for TB, focusing on the needs of patients in lower-income countries. The partnership combines AN2’s boron chemistry platform with GSK’s global health expertise to address urgent treatment gaps.

    Reuters·
    UK
    GSK
    0.00%
    US
    GSK
    -0.03%
    US
    ANTX
    -3.51%
    Reuters·
    UK
    GSK
    0.00%
    US
    GSK
    -0.03%
    US
    ANTX
    -3.51%
    © 2025 Longbridge｜Disclaimer